SCHEMBL5098541

SCHEMBL5098541

C=CCc1ccccc1OCC(=O)OCC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
GAA P10253 2/20 0.56
USP2 O75604 1/20 0.56
LMNA P02545 4/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
NPC1 O15118 1/20 0.51
S1PR4 O95977 1/20 0.51
MAPT P10636 1/20 0.51
ITGA4 P13612 1/20 0.51
HPGD P15428 1/20 0.51
S1PR1 P21453 1/20 0.51
MAPK1 P28482 1/20 0.51
RAB9A P51151 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
TLR9 Q9NR96 1/20 0.51
ABCB1 P08183 1/20 0.49
KDM4E B2RXH2 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4209605 0.87 GAA (0.54) ALDH1A1GAALMNASMN1; SMN2MAPT
SCHEMBL9507379 0.87 USP2 (0.57) ALDH1A1USP2LMNAL3MBTL1SMN1; SMN2
SCHEMBL7329095 0.85 KDM4E (0.56) ALDH1A1GAALMNAMEN1KMT2A
SCHEMBL3259595 0.85 USP2 (0.60) ALDH1A1USP2LMNAMEN1KMT2A
SCHEMBL15550746 0.82 CYP4F2 (0.58) ALDH1A1USP2LMNAL3MBTL1SMN1; SMN2
SCHEMBL3312441 0.82 ALDH1A1 (0.54) ALDH1A1GAALMNAMEN1KMT2A
SCHEMBL8422011 0.81 L3MBTL1 (0.50) ALDH1A1LMNAMEN1KMT2AL3MBTL1
SCHEMBL2010417 0.81 USP2 (0.67) ALDH1A1GAAUSP2LMNAL3MBTL1
SCHEMBL2871402 0.81 PPARD (0.58) ALDH1A1USP2LMNAL3MBTL1SMN1; SMN2
SCHEMBL7235182 0.81 USP2 (0.56) ALDH1A1USP2LMNAL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146631-A1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS BROOKS DAWN ALISA 2008-06-19 US disclosed
US-7351728-B2 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists ELI LILLY AND COMPANY (US) 2008-04-01 US disclosed
EP-1313715-B1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS LILLY CO ELI (US) 2007-08-01 EP disclosed
US-6982278-B2 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists ELI LILLY AND COMPANY (US) 2006-01-03 US disclosed
US-20050250825-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists BROOKS DAWN A 2005-11-10 US disclosed
US-20040024034-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists BROOKS DAWN ALISA (US) 2004-02-05 US disclosed
EP-1313715-A1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2003-05-28 EP disclosed
WO-2002018355-A1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250825-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists PPARA, PPARG, PPARD ALDH1A1 826/4885GAA 2970/4885USP2 2517/4885
US-20040024034-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists PPARA, PPARG, PPARD ALDH1A1 1495/4885GAA 3133/4885USP2 2593/4885
US-20080146631-A1 OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS PPARA, PPARG, PPARD ALDH1A1 936/4885GAA 2971/4885USP2 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.